35 results about "Heart protection" patented technology

The invention discloses a compound composition with a multi-target heart protection function as well as a preparation method and application of the compound composition. The composition is composed of a basic functional oil phase, a core antioxidant / anti-inflammatory phase, a myocardial nutrition and regulation phase and a bioavailability promotion phase in a synergistic manner, and is integrated into a composite cardiac oligopeptide and microencapsulated particle key component substance through a specific enzymolysis and microencapsulation embedding process system. The invention aims to solve the technical problems of single target spot, insufficient synergistic effect of all components, low bioavailability of active components and poor stability of the existing heart protection product, and provides a stable and easily-absorbed composite composition which can realize synergistic effect from multiple channels at the same time. Technical effect verification shows that under the condition of equal-dose sample feeding, the composition can remarkably improve the bioavailability of functional components and shows excellent myocardial cell oxidative damage resistance and myocardial ischemia improvement activity in cell and animal models, the effect is remarkably superior to that of independent use or simple physical mixing of all the components, and the composition is suitable for clinical application. And the substantial progress of synergistic interaction is proved. The composition can be used for developing various medicines, health foods and functional foods beneficial to heart health.

The invention relates to the technical field of active peptides, in particular to a myocardial active peptide capable of relieving heart failure and protecting heart and a preparation method thereof. The method takes pig hearts as raw materials, and sequentially comprises the following steps: pretreating the pig hearts, adding water, and homogenizing; adding alkaline protease to carry out first constant-temperature enzymolysis; adding neutral protease and flavourzyme to carry out second constant-temperature enzymolysis; then lipase is added for third-time constant-temperature enzymolysis, and enzyme deactivation and cooling are carried out; and finally, adding activated carbon into the enzymatic hydrolysate, filtering with diatomite, and spray-drying to obtain the myocardial active peptide. According to the method, the yield and the purity of the active peptide are remarkably improved through a synergistic process of three-step enzymolysis and activated carbon purification, the obtained product is rich in small molecule peptide with a definite heart protection function, and a new way is provided for high-value utilization of pig heart resources and development of functional products for preventing and treating heart failure.

1. The name of this design product: Heart Protector (C). 2. Purpose of this product design: used to protect the heart and regulate blood pressure. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

1. The name of the design product: bracelet (rose and lilac heart protection incense). 2. The use of the design product: jewelry. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective drawing.

The invention belongs to the technical field of experimental animal models, and particularly relates to a construction and analysis method of a zebra fish heart failure model. The invention discloses a construction method of a zebra fish heart failure model. The construction method comprises the following steps: S1, pretreating a zebra fish embryo; and S2, putting the zebra fish embryos pretreated in the step S1 into an exposure solution for exposure, thereby completing the construction of the zebra fish heart failure model. According to the construction and analysis method of the zebra fish heart failure model, accurate induction and dynamic monitoring of heart failure phenotypes are achieved through a standardized drug treatment process and a multi-mode heart function evaluation system, and an efficient platform is provided for cardiovascular drug screening and toxicity evaluation. The construction and analysis method of the zebra fish heart failure model further extends to the field of medicine and functional food heart protection efficacy evaluation, and objective grading authentication of food and medicine efficacy is achieved.

1. Name of the designed product: pendant (650 light moxibustion heart instrument). 2. Use of the designed product: equipment for wearing on the chest to assist in the treatment of cardiovascular diseases. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view.

The present invention discloses a heart-protective complex composition for improving the absorption rate of Coenzyme Q10 and a preparation method thereof, relating to the technical field of medicine and functional foods. The core active ingredients comprise Coenzyme Q10, Vitamin E, and black pepper extract within a specific mass ratio range. Pharmaceutically acceptable carriers and antioxidant synergists may also be combined to prepare various oral dosage forms. By constructing a ternary active component system with a specific ratio, the present invention achieves temporal synergy between absorption promotion and antioxidant regeneration in vivo, thereby solving the technical problems of low oral bioavailability and insufficient myocardial targeted accumulation of existing Coenzyme Q10 preparations. It significantly enhances the conversion efficiency of Coenzyme Q10 into the active form available to myocardial cells, and can be widely used in the preparation of drugs or functional foods for preventing or treating heart diseases.

The application discloses a C-19 modified isosteviol derivative and a preparation method and application thereof, aims to provide an isosteviol derivative with a heart protection activity, transforms a C-19 position of isosteviol, converts a C-19 position carboxyl into a primary amine or isocyanic acid by using a Curtius rearrangement, and further modifies the primary amine to introduce a fatty acid, aromatic acid fragment to convert into an amide fragment, or converts the isocyanic acid into a urea fragment, obtains a series of novel nitrogen-containing isosteviol derivatives by a strategy of reducing one carbon atom, and the nitrogen-containing isosteviol derivatives show good heart protection activity on a zebra fish model of myocardial injury, and can be used for preparing heart protection drugs, and the application relates to the technical field of medicines.

Disclosed are compositions and methods for treating Duchenne muscular dystrophy. The compositions include a micro-dystrophin having a dystrophin N-terminal domain, a dystrophin R16 domain, a dystrophin R17 domain, a dystrophin R18 domain, a dystrophin R19 domain, and a dystrophin CR domain. The compositions are particularly useful for treating Duchenne muscular dystrophy and for treating cardiac arrhythmia in subjects having or suspected of having Duchenne muscular dystrophy.

This invention belongs to the field of pharmaceutical technology, and relates to diphenylmethane derivatives, their preparation methods, and applications. The diphenylmethane derivative is a compound represented by Formula I, its optical isomer, or a pharmaceutically acceptable salt thereof: wherein X is CH2; Y is selected from: -NH-, -CO-, -NHCONH-. The diphenylmethane derivative of this invention is stable, easy to store, and readily prepared, exhibiting good feasibility. It demonstrates outstanding in vitro and in vivo efficacy and good safety profile when used to prepare anticardioprotective drugs (for heart failure and myocardial hypertrophy).

The application discloses a ginsenoside-protopanaxadiol hydrogen sulfide donor derivative, a preparation method and application thereof, and belongs to the technical field of natural medicines and medicinal chemistry. Ginsenoside-protopanaxadiol is used as a lead compound, a series of ginsenoside-protopanaxadiol hydrogen sulfide donor derivatives are designed and synthesized, and myocardial protection activities of the synthesized derivatives are tested. The results show that the ginsenoside-protopanaxadiol hydrogen sulfide donor derivative prepared by the application has better cardiac protection activities for treating myocardial ischemia, arrhythmia and myocardial infarction, and has the potential as a cardiac protection drug.

The invention discloses a therapeutic target for acute myocardial infarction complicated with stress hyperglycemia and application of the therapeutic target. The invention also discloses an application of the substance for inhibiting the FOXK2 glycosylation level in preparation of a product for treating acute myocardial infarction combined with the stress hyperglycemia disease, and discloses a short peptide for treating the acute myocardial infarction combined with the stress hyperglycemia disease. The amino acid sequence of the oligopeptide is sequence 1. Experiments prove that under the condition of high glucose, the oligopeptide can be competitively combined with glycosyltransferase OGT so as to inhibit the glycosylation level of FOXK2, so that the protective effects of inhibiting a downstream inflammation pathway and relieving heart injury are achieved. The method is of great significance in improving understanding of endogenous protection mechanisms after myocardial infarction and searching intervention targets of heart protection strategies after myocardial infarction.

The invention discloses a 3D hypoxia cultured stem cell-derived exosome as well as a preparation method and application thereof, belongs to the technical field of derivative products of cells, and solves the problem that in the prior art, the functional difference between an in-vitro cultured stem cell-derived exosome and an in-vivo naturally generated exosome is large. Compared with the traditional 2D normal oxygen culture stem cell source exosome, the 3D low oxygen culture stem cell source exosome provided by the invention has the advantages that the particle concentration and the protein concentration are obviously improved, the abundance of miRNA (micro Ribonucleic Acid) related to heart protection contained in the 3D low oxygen culture stem cell source exosome is higher, and the 3D low oxygen culture stem cell source exosome has a stronger promotion effect on the proliferation of human umbilical vein endothelial cells; and the compound has a more obvious promotion effect on tubulation and migration of human umbilical vein endothelial cells.

The invention discloses a flexible expandable isolating device for heart-protecting moxibustion, specifically relating to the technical field of medical devices. The invention includes: a base cylinder, the top end of the base cylinder is screw-sleeved with a connecting cylinder, a moxibustion mesh is clamped between the connecting cylinder and the base cylinder, the top end of the connecting cylinder is screw-inserted with an adjustment cylinder, the top end of the adjustment cylinder is installed with a mounting base, and the mounting base is fixed with a moxa cone; a threaded ring is arranged at the top end of the base cylinder, and a plurality of limiting slots are formed at the connection between the threaded ring and the base cylinder; a plurality of connecting tabs are arranged on the edge of the moxibustion mesh, and each of the connecting tabs respectively engages with a corresponding limiting slot; the connecting cylinder and the adjustment cylinder are screw-connected and cooperate to adjust the height of the moxa cone; and anti-slip grooves are formed on the exterior of the connecting cylinder. The present invention allows convenient adjustment of the moxibustion distance when the temperature is excessively high, enables modification of the moxibustion surface area as needed, and ensures secure installation of the moxibustion mesh. It effectively addresses the issues of difficult temperature adjustment, unchangeable moxibustion surface area, and loose moxibustion mesh in traditional heart-protecting moxibustion devices, demonstrating strong practicality.

The invention discloses a heart protection moxibustion preparation technology based on traditional Chinese medicine treatment and a use method thereof, and particularly relates to the technical field of heart protection moxibustion, the heart protection moxibustion preparation technology comprises the following steps: S1, medicine formula development, S2, moxibustion tool design, and the use method comprises the following steps: S1, accurate acupuncture point positioning, S2, moxibustion therapy scheme making, and S3, moxibustion therapy process optimization. According to the invention, the medicine formula and dosage form are optimized through the modern technology to improve the curative effect, the moxibustion tool design is innovated to guarantee safety and comfort, precise personalized treatment is realized by means of advanced means, and the comprehensive management system cooperates with each module to provide support for optimization treatment and process improvement, and brings better traditional Chinese medicine treatment experience.

The invention belongs to the technical field of medicines, and relates to a 2, 4-disubstituted pyridine derivative, in particular to a compound as shown in a formula (II) and structural forms such as nitrogen oxides, isomers, solvates and pharmaceutically acceptable salts of the compound. Furthermore, the invention also discloses a preparation method and pharmaceutical application of the 2, 4-disubstituted pyridine derivative, and the 2, 4-disubstituted pyridine derivative can be used as a PI3Kalpha agonist and is used for preventing or treating PI3Kalpha activation-related body disorder and the like, including but not limited to heart protection of ischemia reperfusion injury, neuron regrowth after nerve injury and the like.

The invention discloses an application of a vinegar trogopterus dung water extract in preparation of a product for protecting heart and / or resisting platelet aggregation thrombosis. Research finds that the vinegar trogopterus dung water extract has a heart protection effect, and particularly, the heart rate, cardiac output and blood flow velocity are improved. The vinegar trogopterus dung water extract has the effect of resisting platelet aggregation thrombosis, and specifically, the dyeing intensity of heart red blood cells is increased. The vinegar trogopterus dung water extract is applied to heart protection and / or platelet aggregation thrombus resistance, and has high efficiency and safety.

A protein selected from the group consisting of Chrdl1, Fam3c, Fam3b and fragments thereof, or a polynucleotide encoding the protein, for use in treating or reducing the risk of heart disease.

The invention relates to the technical field of pet heart protection, and discloses a preparation method of a functional health-care product for pet heart and a health-care product of the functional health-care product for pet heart. The preparation method comprises the following steps: mixing 97-99 parts of decanoic acid medium chain triglyceride, 0.5-1.5 parts of astaxanthin and 0.5-1.5 parts of lycopene, and stirring at a certain temperature until the mixture is completely dissolved to obtain a first mixture; s2, placing the obtained first mixture in a high-pressure homogenizer, and homogenizing the first mixture under 90-110 Mpa to prepare a microemulsion; s3, adsorbing the microemulsion into microcapsule particles by using silicon dioxide and corn starch; and S4, uniformly mixing 35-45 parts by mass of the microcapsule particles, 15-25 parts by mass of the chicken liver powder, 2-8 parts by mass of the yeast hydrolysate and 30-40 parts by mass of microcrystalline cellulose, and granulating. The health-care product prepared by the preparation method of the functional health-care product for the pet heart has better effects of relieving inflammation and better absorption.

The present research aims at successfully establishing a rat acute heart failure model, observing the heart pathological changes of the animal and detecting the heart and blood related indexes to evaluate the stability of the model, so as to make the rat acute heart failure model with short model making period, stable heart failure characteristics, good repeatability and closeness to clinic, facilitate the further research on the pathogenesis and pathophysiological changes of the acute heart failure model and provide certain basis for how to implement the heart protection intervention measures. The rat acute heart failure model construction method of the present application is to inject acetone and isopropyl alcohol into the vein of the rat, stimulate with electromagnetic waves, frighten with sound, stimulate with formaldehyde and stimulate with potassium permanganate, so as to induce the rat acute heart failure model with short model making period, stable heart failure characteristics, good repeatability and closeness to clinic. The rat acute heart failure model constructed by the present application only needs 10 days, the heart failure characteristics are stable, the model is closer to the clinical symptoms and has high repeatability.

The present invention belongs to the field of biomedicine technology and specifically relates to the use of piR-mmu-57256903 in the preparation of a drug for preventing and treating heart diseases caused by anticancer drugs. The piR-mmu-57256903 can regulate histone methylation by regulating the activity of methylases / demethylases, thereby affecting the expression of apoptosis-related proteins, and playing an important regulatory role in pathological processes related to oxidative stress and cell apoptosis. Based on this principle, the present invention uses piR-mmu-57256903 as a target to prevent and treat various heart diseases caused by the administration of anticancer drugs, improve cardiac function, and provide cardiac protection for cancer patients after the administration of anticancer drugs. It also provides new drug development pathways and drug action targets for the diagnosis and treatment of heart failure or myocardial damage in cancer patients after drug treatment, and has very important pharmaceutical value.

The application discloses a use of a larazotide polypeptide in preparation of a drug for relieving adriamycin cardiotoxicity. In-vivo experimental results show that the larazotide can effectively relieve the toxic effect of a chemotherapeutic drug adriamycin on the heart, relieve myocardial enzyme spectrum increase, enhance left ventricular diastolic capacity and cardiac ejection fraction by improving body and heart immune cell homeostasis and reducing myocardial tissue cell apoptosis, thereby reducing the toxic side effect of the chemotherapeutic drug adriamycin, and improving intestinal barrier function damage caused by adriamycin chemotherapy. The application overcomes the defects of current clinical drug limitations of Dox and existing chemotherapeutic heart protection drugs, and solves the prevention and treatment problems of heart toxicity and intestinal side effects induced in Dox chemotherapy.

The invention discloses an application of repiperidine in heart protection. The invention relates to an application of repiperidine in preparation of a medicine for treating and / or preventing myocardial infarction. Before myocardial infarction operation, a mouse is pretreated by repiperidine, so that the number of reactive oxygen species (ROS) positive cells and TUNEL positive cells is reduced. After the repiperidine is used for pretreatment, the myocardial infarction area of the mouse is reduced, and the ejection fraction (EF%) of the mouse with myocardial infarction is improved.

The invention belongs to the technical field of medical big data analysis and intelligent medical treatment, and discloses a cardiovascular disease full-cycle diagnosis and treatment management system based on multi-modal data fusion. The system comprises a mobile wearing data acquisition module, a multi-modal data fusion module, an equipment linkage control module, a first-aid collaborative response module and a full-period management center module. Heart rate, blood pressure, blood oxygen and dynamic electrocardiosignals are continuously collected through a heart protection instrument, unified access is conducted on the heart rate, the blood pressure, the blood oxygen and the dynamic electrocardiosignals, hospital historical diagnosis and treatment data and living habit data, multi-source data are fused through an attention mechanism and a graph neural network, an individualized dynamic health baseline is established, and health state evaluation and cardiovascular event early warning results are output; physiotherapy, retest and medication reminding are automatically linked according to an evaluation result, and first-aid linkage is triggered when a preset high-risk condition is met. According to the system, deep fusion of cardiovascular disease multi-modal data and closed-loop management of monitoring, early warning, intervention and emergency treatment are realized, and the early warning accuracy and the emergency treatment response efficiency are improved.

The present application belongs to the technical field of biological medicine, and particularly relates to application of a reagent or method for inhibiting expression of lysine-specific demethylase 6B in preparation of a drug for preventing and treating heart diseases caused by administration of anticancer drugs. The present application inhibits the activity of a downstream target gene p53 by inhibiting expression of histone demethylation transferase member lysine-specific demethylase 6B, and affects the expression of an apoptosis-related protein, thereby playing an important promoting role in a pathological process related to cell apoptosis. Based on this principle, the present application takes lysine-specific demethylase 6B as a target to prevent and treat heart diseases caused by administration of anticancer drugs, improves heart function, provides heart protection for tumor patients after administration of anticancer drugs, and also provides a new drug research and development approach and a drug action target for diagnosis and treatment of heart failure or myocardial injury of tumor patients after drug treatment, and has very important medicinal value.

The invention discloses a C-19 site modified isosteviol derivative as well as a preparation method and application thereof. The invention aims to provide an isosteviol derivative with cardiac protection activity. The method comprises the following steps: modifying C-19 site of isosteviol, converting C-19 site carboxyl into primary amine or isocyanic acid by utilizing corius rearrangement, further modifying the primary amine, introducing fatty acid, converting aromatic acid fragments into amide fragments, or converting isocyanic acid into urea fragments, and obtaining a series of novel nitrogen-containing isosteviol derivatives through a strategy of reducing one carbon atom. The compound shows good heart protection activity on a myocardial injury zebrafish model, and can be used for preparing heart protection drugs. The invention relates to the technical field of medicines.

1. The name of the design product: pendant (treasure gourd light moxibustion heart instrument). 2. The use of the design product: equipment for wearing on the chest to assist in the treatment of cardiovascular. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: reference figure 1 in use.

The invention discloses an application of a Fe3O4 (at) ZIF-8 nano-enzyme in preparation of a medicine for treating myocardial injury, the Fe3O4 (at) ZIF-8 nano-enzyme is of a core-shell structure which takes Fe3O4 as a nano-enzyme and is externally coated with ZIF-8, the overall average particle size of the nano-enzyme is (12-22) nm, it can be ensured that the ultra-small nano-enzyme has good dispersity and myocardial tissue accessibility, and the nano-enzyme can be used as a medicine for treating myocardial injury. And a ZIF-8 shell layer is utilized to stabilize the enzyme-like activity of Fe3O4 and regulate and control the microenvironment, so that additional oxidative damage caused by free iron is reduced, and the material as a main body plays a multi-dimensional mechanism of oxidation resistance, inflammation resistance and mitochondria protection. According to the invention, the Fe3O4 ZIF-8 nano-enzyme is applied to drug-induced myocardial injury for the first time, and it is found that the nano-enzyme shows a remarkable heart protection effect. The Fe3O4 ZIF-8 nano-enzyme can be prepared on a large scale, is good in biocompatibility, and has a wide application prospect in drug cardiotoxicity intervention and other ROS / inflammation related heart diseases.

The invention relates to a hydroxypropylamine compound as shown in a formula I and pharmaceutically acceptable salt of the hydroxypropylamine compound. The invention further relates to medical application of the hydroxypropyl cyclic amine compound and the pharmaceutically acceptable salt of the hydroxypropyl cyclic amine compound, and the compound shown in the formula I has an anti-tumor function by blocking a ubiquitination-like Neddylation pathway; the compound shown in the formula I has beta-adrenergic receptor retarding activity and anti-inflammatory and anti-oxidation activity, and plays a role in protecting the heart; the external embodies of the anti-tumor function and the heart protection function are respectively remarkable anti-tumor activity and heart protection activity.

The invention discloses application of dapagliflozin in preparation of a preparation for regulating intestinal microbiota composition and plasma metabonomics characteristics of a heart failure patient, and belongs to the technical field of biology. According to the application of the dapagliflozin in preparing the preparation for regulating the intestinal microbiota composition and plasma metabonomics characteristics of the heart failure patient, the dapagliflozin regulates the intestinal microbiota composition of the HF patient, remodels the plasma metabonomics characteristics and influences the microorganism-metabolite interaction. These findings show that dapagliflozin exerts a cardiac protective effect at least to some extent by intestinal-mandrel modulation. This comprehensive analysis provides a new mechanism insight in addition to hypoglycemic, and supports an HF precise treatment strategy for microbiota.